Stockscreener 앱 받기
10.99
0.37%
0.04
전일 마감가:
$10.95
열려 있는:
$11.01
하루 거래량:
1.72M
Relative Volume:
1.63
시가총액:
$577.19M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.7446
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-15.20%
1개월 성능:
-9.84%
6개월 성능:
+57.22%
1년 성능:
+10.23%
1일 변동 폭
$10.90
$11.47
1주일 범위
$10.90
$12.83
52주 변동 폭
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.99 | 575.09M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Moving Averages: Will Norfolk Southern Corporation outperform tech stocksJuly 2025 Catalysts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Ex-Biotech CEO Cashed In $10M Ahead Of COVID Vaccine Crisis: Lawsuit - AOL.com
JPM movers: ImmunityBio rises to the top - BioCentury
FRAUD AND MANIPULATION—N.Y. Sup.: New York’s AG sues former Emergent BioSolutions CEO for insider trading - VitalLaw.com
Insider Sell: Can BOS Better Online Solutions Ltd disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Retail Trends: Is CMREPRC stock technically oversoldEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Lobbying Update: $430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading - The New York Times
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading - BioPharma Dive
Emergent BioSolutions (EBS) Receives a New Order from US Department of War - Insider Monkey
Former biotech CEO sued over COVID vaccine alleged insider trading - AOL.com
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement - Intellectia AI
Read This Before Judging Emergent BioSolutions Inc.'s (NYSE:EBS) ROE - Yahoo Finance
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination - 1470 & 100.3 WMBD
New Packaging Option for Narcan Nasal Spray Aims to Reduce Stigma - Psychiatry Advisor
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading - Law360
Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - The Wall Street Journal
Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination - Reuters
NY Sues Ex-Emergent BioSolutions CEO for Insider Trading (1) - Bloomberg Law News
Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4%What's Next? - MarketBeat
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update - marketscreener.com
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline - Sahm
Emergent BioSolutions makes $100 million voluntary loan prepayment By Investing.com - Investing.com Nigeria
Emergent BioSolutions Inc CEO Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet? - 富途牛牛
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness - The Manila Times
FDA clears discreet NARCAN case to help more people carry overdose spray - Stock Titan
Emergent BioSolutions, Inc. Announces Voluntary Prepayment of $100 Million Under its Outstanding Term Loan Facility - marketscreener.com
Emergent BioSolutions Announces $100 Million Loan Paydown - citybiz
Emergent BioSolutions makes $100 million voluntary loan prepayment - Investing.com
Emergent BioSolutions Inc Announces $100 Million Term Loan Prepayment - TradingView — Track All Markets
Emergent BioSolutions announces $100 million paydown of term loan principal, a significant step achieved toward its multi-year transformation - marketscreener.com
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation - The Manila Times
Star Tribune - FinancialContent
Market Review: Is Emergent BioSolutions Inc currently under institutional pressureJuly 2025 Short Interest & Weekly Momentum Stock Picks - baoquankhu1.vn
Published on: 2026-01-10 21:10:13 - Улправда
Will Emergent BioSolutions Inc. stock gain from government policiesJuly 2025 Trends & Accurate Entry and Exit Point Alerts - Улправда
Will Emergent BioSolutions Inc. stock maintain growth storyQuarterly Trade Summary & Community Driven Trade Alerts - Улправда
Can Emergent BioSolutions Inc. stock rebound after recent weaknessMarket Volume Summary & Stock Timing and Entry Methods - ulpravda.ru
Emergent BioSolutions (EBS) Secures $21.5M U.S. Defense Order fo - GuruFocus
Emergent BioSolutions Receives $21.5 Million Delivery Order for BioThrax - marketscreener.com
Emergent BioSolutions receives $21.5 million order from U.S. Department of War to supply Biothrax in 2026 - marketscreener.com
Emergent BioSolutions Secures $21.5 Million Order for BioThrax® Anthrax Vaccine from U.S. Department of War - Quiver Quantitative
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 - The Spec
Emergent BioSolutions partners with PANTHER on mpox treatment trial By Investing.com - Investing.com Canada
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa - The Manila Times
EBS (NYSE: EBS) insider files notice to sell 25,748 common shares - Stock Titan
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.45%
자본화:
|
볼륨(24시간):